Annual report pursuant to Section 13 and 15(d)

Significant Strategic Collaborations (Details Narrative)

v3.22.1
Significant Strategic Collaborations (Details Narrative) - USD ($)
 3 Months Ended 12 Months Ended
Oct. 12, 2021
Jun. 12, 2020
May 15, 2020
Sep. 30, 2019
Dec. 31, 2021
Dec. 31, 2020
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Research and development expenses         $ 3,163,485 $ 1,731,406
Prepaid expenses and other         200,000 200,000
Prepaid expenses and other         300,000 200,000
Payments for aggregate amount         100,000  
One-time payment $ 21,000          
Revenues         1,160,692 436,942
Master Services Agreement [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Prepaid expenses and other         25,000 25,000
Payments for aggregate amount         $ 1,050,000  
Issuance of stock         1,000,000  
Co-Development Agreement [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Revenues         $ 0 0
Pharmsynthez [Member] | Series B Preferred Stock [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Warrants outstanding         1,500,000  
Takeda [Member] | Royalty Revenue [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Revenue         $ 1,200,000 $ 400,000
Scripps Research [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Research and development expenses     $ 3,000,000.0   $ 2,100,000  
Initial payment for research     300,000      
Quarterly payments     $ 300,000      
Pharmsynthez [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Research and development expenses       $ 350,000    
Percent ownership in Xenetic         3.30% 5.10%
Payment for Pharmsynthez 40,000 $ 51,000        
Costs and expenses $ 19,000          
Pharmsynthez [Member] | Master Services Agreement [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Research and development expenses         $ 100,000 $ 200,000